Prognostic study of 229 follicular lymphoma patients treated with rituximab combined with chemotherapy.
10.3760/cma.j.issn.0253-2727.2019.01.009
- Author:
Nan WANG
1
,
2
;
Peng Peng XU
;
Li WANG
;
Shu CHENG
;
Wei Li ZHAO
;
Hui Ping SUN
Author Information
1. Key Laboratory of Medical Genomics
2. Shanghai Institute of Hematology, Shanghai Ruijin Hospital, Shanghai 200025, China.
- Publication Type:Journal Article
- Keywords:
Lymphoma, follicular;
Prognosis;
Rituximab
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Cyclophosphamide;
Disease-Free Survival;
Doxorubicin;
Humans;
Lymphoma, Follicular/drug therapy*;
Prednisone;
Prognosis;
Retrospective Studies;
Rituximab/therapeutic use*;
Vincristine
- From:
Chinese Journal of Hematology
2019;40(1):46-51
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To explore the clinical characteristics of follicular lymphoma (FL) in the era of rituximab combined with chemotherapy and the prognostic significance of the follicular lymphoma international prognostic index (FLIPI), follicular lymphoma international prognostic index 2 (FLIPI2), international prognostic index (IPI), revised international prognostic index (R-IPI), National Comprehensive Cancer Network international prognostic index (NCCN-IPI) among Chinese patients. Methods: 229 FL patients who were treated initially with rituximab combined with CHOP-like (cyclophosphamide, doxorubicin, vincristine and prednisone) chemotherapy from November 2008 to April 2018 were analyzed retrospectively and all were scored by the above clinical index. Univariate and multivariate survival analysis were performed on 201 patients who completed the treatment and were followed regularly. Results: In the univariate survival analysis, age>60 years, hemoglobin<120 g/L, elevated serumβ(2)- macroglobulin, involvement of bone marrow and elevated CRP were the risk prognostic factors for overall survival (OS) and progression free survival (PFS). Moreover, the analysis of the OS and PFS between rituximab (R) maintenance (RM) group and non-maintenance (non-RM) group showed that the OS and PFS of RM group were better than those of non-RM. In the multivariate analysis of OS, hemoglobin<120 g/L, involvement of bone marrow, elevated CRP and non-RM were independent prognostic factors. In the multivariate analysis of PFS, hemoglobin<120 g/L, CRP and non-RM were independent prognostic factors. When FLIPI2 was included in the multivariate analysis, CRP and FLIPI2 were independent prognostic factors in both OS and PFS, and non-RM was independent prognostic factors in PFS. Conclusion: FLIPI2 is the better risk stratification in FL patients in the era of rituximab.
